Master the design and operation of perfusion cell cultures with this authoritative reference. Discover the current state-of-the-art in the design and operation of continuous bioreactors, with emphasis on mammalian cell cultures for producing therapeutic proteins. Topics include the current market for recombinant therapeutic proteins, current industry challenges and the potential contribution of continuous manufacturing. Provides coverage of every step of process development and reactor operation, including small scale screening to lab-scale and scale-up to manufacturing scale. Illustrated through real-life case studies, this is a perfect resource for groups active in the cell culture field, as well as graduate students in areas such as chemical engineering, biotechnology, chemistry and biology, and to those in the pharmaceutical industry, particularly biopharma, biotechnology and food or agro industry.

In the fall of 1980, Genentech, Inc., a little-known California genetic engineering company, became the overnight darling of Wall Street, raising over $38 million in its initial public stock offering. Lacking marketed products or substantial profit, the firm nonetheless saw its share price escalate from $35 to $89 in the first few minutes of trading, at that point the largest gain in stock market history. Coming at a time of economic recession and declining technological competitiveness in the United States, the event provoked banner headlines and ignited a period of speculative frenzy over biotechnology as a revolutionary means for creating new and better kinds of pharmaceuticals, untold profit, and a possible solution to national economic malaise. Drawing from an unparalleled collection of interviews with early biotech players, Sally Smith Hughes offers the first book-length history of this pioneering company, depicting Genentech's improbable creation, precarious youth, and ascent to immense prosperity. Hughes provides intimate portraits of the people significant to Genentech's science and business, including cofounders Herbert Boyer and Robert Swanson, and in doing so sheds new light on how personality affects the growth of science. By placing Genentech's founders, followers, opponents, victims, and beneficiaries in context, Hughes also demonstrates how science interacts with commercial and legal interests and university research, and with government regulation, venture capital, and commercial profits. Integrating the scientific, the corporate, the contextual, and the personal, "Genentech" tells the story of biotechnology as it is not often told, as a risky and improbable entrepreneurial venture that had to overcome a number of powerful forces working against it.

The Silicon phenomenon was, is, and will be an extremely important phenomenon in the accelerated technological, scientific, and economic development of countries and regions. Silicon Valley North (SVN) is the high tech capital of Canada, the nation??'s most developed and dynamic technology sector, which includes multiple clusters in telecommunications, software, photonics, and life sciences. It gave birth to many well-known companies such as Corel, JDS Uniphase, Mitel, Newbridge Networks, Nortel Networks, Digital Equipment of Canada, just to mention a few. A lot of literature describes Silicon Valley and Silicon Alley in the US, Silicon Islands in Asia, and so on. Despite the quite evident importance of Silicon Valley North for the regional, national, and international technological development (especially when Nortel Networks and JDS Uniphase became global leaders in their fields and expanded in explosive fashion), this phenomenon is far from being well understood. Because of this, a book on the Canadian Silicon Valley is an exceptionally timely endeavor.
Silicon Valley North: A High-Tech Cluster of Innovation and Entrepreneurship is devoted to the multidimensional and multifaceted nature of SVN, its history, current state and future developments. The book offers a broad and deeply thematic analysis of one particular innovative cluster???Silicon Valley North. The reader will obtain expert insight into what SVN is all about by acquiring a comprehensive and "panoramic picture" of SVN within a single book. The reader will develop an accurate sense of what spurs high tech start-up companies in SVN toward their exceptional performances, and how to apply these insights to his or herunique regional context.

Masters of Doom is the true inside story of the Lennon and McCartney of the video game industry: John Carmack and John Romero. Together they created an empire, ruled a multibillion-dollar industry, and provoked a national controversy. They lived a unique American dream, escaping their broken homes to co-create the most innovative and notoriously successful video games in history - Doom and Quake - until the games they made tore them apart. David Kushner has been covering the video game industry for ten years and knows all the angles. Even those with no interest in video games will be fascinated by this vastly entertaining tale of friendship, betrayal and the genesis of a multibillion-dollar popular art form.

Scientists in the biotechnology sector have developed a vast array of products and procedures, including drugs, diagnostics, agricultural products and veterinary procedures. This is made possible through various intra- and inter-organizational collaborations between the academic and private sectors, and through the establishment of networks for learning. In Networks for Learning and Knowledge Creation in Biotechnology, Amalya Lumerman Oliver shows how, in many respects, the organizational structure of the industry parallels one of its most important innovations - recombinant DNA (rDNA). She shows how the concept of recombination can be used to explain a number of organizational elements, including biotechnology firms, the form of university-based spin-offs, scientific entrepreneurship, and trust and contracts in learning collaborations and networks. The result is a stimulating account of how multiple theoretical perspectives can be used to understand the structure of the biotechnology industry.

This is a full-length history of the Western Electric Company, which was the manufacturing arm of the Bell System. As manufacturer in the communications revolutions in the nineteenth and twentieth centuries, Western Electric made products that accelerated society's pace, such as telegraphs, telephones, an early computing machine, radios, radar and transistors. Western's history offers numerous examples of the difference between innovation and implementation. The aftermath of Western's 1882 acquisition by Bell Telephone, for instance, reveals vertical integration as a lengthy process rather than a single event. Ironically, although Western transformed business worldwide with innovations in areas such as quality control and industrial psychology, the company was slow to implement these innovations itself. Western's dual role as captive supplier for a regulated monopoly and as government contractor led to its most rapid change, in the area of civil rights.

Manufacturing the Future: A History of Western Electric is the first full-length history of the Western Electric Company, the manufacturing arm of the Bell System. As a manufacturer in the communications revolutions in the nineteenth and twentieth centuries, Western Electric made new products such as telegraphs, telephones, an early computing machine, radios, radar, and transistors. The book demonstrates, through Western's 1882 acquisition by Bell Telephone, that vertical integration was a lengthy process rather than a single event. It also shows the coming of age of industrial psychology and describes the advent of civil rights in corporate America.

Agricultural (or "green") biotechnology is a source of growing tensions in the global trading system, particularly between the United States and the European Union. Genetically modified food faces an uncertain future. The technology behind it might revolutionize food production around the world. Or it might follow the example of nuclear energy, which declined from a symbol of socioeconomic progress to become one of the most unpopular and uneconomical innovations in history.

This book provides novel and thought-provoking insights into the fundamental policy issues involved in agricultural biotechnology. Thomas Bernauer explains global regulatory polarization and trade conflict in this area. He then evaluates cooperative and unilateral policy tools for coping with trade tensions. Arguing that the tools used thus far have been and will continue to be ineffective, he concludes that the risk of a full-blown trade conflict is high and may lead to reduced investment and the decline of the technology. Bernauer concludes with suggestions for policy reforms to halt this trajectory--recommendations that strike a sensible balance between public-safety concerns and private economic freedom--so that food biotechnology is given a fair chance to prove its environmental, health, humanitarian, and economic benefits.

This book will equip companies, farmers, regulators, NGOs, academics, students, and the interested public--including both advocates and critics of green biotechnology--with a deeper understanding of the political, economic, and societal factors shaping the future of one of the most revolutionary technologies of our times.

Digital Innovation for Healthcare in COVID-19 Pandemic: Strategies and Solutions provides comprehensive knowledge and insights on the application of information technologies in the healthcare sector, sharing experiences from leading researchers and academics from around the world. The book presents innovative ideas, solutions and examples to deal with one of the major challenges of the world, a global problem with health, economic and political dimensions. Advanced information technologies can play a key role in solving problems generated by the COVID-19 outbreak. The book addresses how science, technology and innovation can provide advances and solutions to new global health challenges. This is a valuable resource for researchers, clinicians, healthcare workers, policymakers and members of the biomedical field who are interested in learning how digital technologies can help us avoid and solve global disease dissemination.

In The Capacity to Innovate, Sarah Giest provides insight into the collaborative and absorptive capacities needed to provide public support to local innovation through cluster organizations. The book offers a detailed view of the vertical, multi-level, and horizontal dynamics in clusters and cluster policy and addresses how they are managed and supported. Using the biotechnology field as an example, Giest highlights challenges in the collaborative efforts of public bodies, private companies, and research institutes to establish a successful ecosystem of innovation in this sector. The book argues that cluster policy in collaboration with cluster organizations should focus on absorptive and collaborative capacity elements missing in the cluster context in order to improve performance. Currently, governments operate at different levels - from the local to the supranational - in order to support clusters, and cluster policies are often pursued alongside other programs, leading to uncoordinated efforts and ineffective cluster strategies. The Capacity to Innovate advocates for a coordinated effort by government and cluster organizations to support capacity elements lacking within the specific cluster context.

Agricultural (or "green") biotechnology is a source of growing tensions in the global trading system, particularly between the United States and the European Union. Genetically modified food faces an uncertain future. The technology behind it might revolutionize food production around the world. Or it might follow the example of nuclear energy, which declined from a symbol of socioeconomic progress to become one of the most unpopular and uneconomical innovations in history. This book provides novel and thought-provoking insights into the fundamental policy issues involved in agricultural biotechnology. Thomas Bernauer explains global regulatory polarization and trade conflict in this area. He then evaluates cooperative and unilateral policy tools for coping with trade tensions. Arguing that the tools used thus far have been and will continue to be ineffective, he concludes that the risk of a full-blown trade conflict is high and may lead to reduced investment and the decline of the technology. Bernauer concludes with suggestions for policy reforms to halt this trajectory--recommendations that strike a sensible balance between public-safety concerns and private economic freedom--so that food biotechnology is given a fair chance to prove its environmental, health, humanitarian, and economic benefits. This book will equip companies, farmers, regulators, NGOs, academics, students, and the interested public--including both advocates and critics of green biotechnology--with a deeper understanding of the political, economic, and societal factors shaping the future of one of the most revolutionary technologies of our times.

This book integrates a science and business approach to provide an introduction and an insider view of intellectual property issues within the biotech industry, with case studies and examples from developing economy markets. Broad in scope, this book covers key principles in pharmaceutical, industrial, and agricultural biotechnology within four parts. Part 1 details the principles of intellectual property and biotechnology. Part 2 covers plant biotechnology, including biotic and abiotic stress tolerance, GM foods in sustainable agriculture, microbial biodiversity and bioprospecting for improving crop health and productivity, and production and regulatory requirements of biopesticides and biofertilizers. The third part describes recent advances in industrial biotechnology, such as DNA patenting, and commercial viability of the CRISPR/Cas9 system in genome editing. The final part describes intellectual property issues in drug discovery and development of personalized medicine, and vaccines in biodefence. This book is an ideal resource for all postgraduates and researchers working in any branch of biotechnology that requires an overview of the recent developments of intellectual property frameworks in the biotech sector.

'A terrifying story of profit before patients, and a chilling glimpse of what can happen when private companies are allowed to take charge of healthcare.' Gavin Francis Six decades ago, researchers achieved the impossible: developing a treatment that transformed kidney failure from a death sentence to a manageable condition. Yet, in the hands of a predatory medical industry, this triumph led to skyrocketing costs and worsening care. A gripping account of privatised healthcare gone wrong, How to Make a Killing recounts how the optimism of the 1950s and 1960s - when transplants and dialysis machines offered hope - gave way to anguished debates about the ethics of rationing and profiting from life-saving care, and how Big Dialysis proliferated at the expense of its patients. A triumph of investigative research, Tom Mueller's book features an unforgettable cast of characters: CEOs who dress as musketeers to exhort more aggressive profit-seeking, nephrologist insiders who reveal the substandard care this causes, and heroic patients who risk their lives to reveal the truth.

Translational Biotechnology: A Journey from Laboratory to Clinics presents an integrative and multidisciplinary approach to biotechnology to help readers bridge the gaps between fundamental and functional research. The book provides state-of-the-art and integrative views of translational biotechnology by covering topics from basic concepts to novel methodologies. Topics discussed include biotechnology-based therapeutics, pathway and target discovery, biological therapeutic modalities, translational bioinformatics, and system and synthetic biology. Additional sections cover drug discovery, precision medicine and the socioeconomic impact of translational biotechnology. This book is valuable for bioinformaticians, biotechnologists, and members of the biomedical field who are interested in learning more about this promising field.

The book examines the evolution of one of the most important technologies that has emerged in the last fifty years: biotechnology - the use of living organisms, or parts thereof to create useful products and services. The most important application of biotechnology has been in medicine, in the development of new drugs. The central purpose of the book is to explain how firms based in the US took the lead in commercialising the technology, and why it has been so difficult for firms in other countries to match what the leading American companies have achieved. The book looks at the institutions and policies which have underpinned US success in biotechnology. This is the US innovation "ecosystem," and it is made up of several interlocking elements which constitute a powerful competitive advantage for US biotechnology firms. These include, a higher education system which has close links with industry, massive support from the Federal government for biomedical research, and a financial system which is well equipped to support young entrepreneurial firms in a science-based industry. In the light of US experience the book examines in detail the performance of UK biotechnology firms over the past forty years, starting with the creation of the UK's first dedicated biotech firm, Celltech, in 1980. The book shows how the UK made a promising start in the 1980s and 1990s but failed to build on it. Several leading firms failed, and after an initial burst of enthusiasm investors lost confidence in the British biotech sector. It is only the last few years that the sector has staged a revival, attracting fresh investment from the US as well from the UK. The story told in this book, based on extensive interviews with industry participants, investors, and policy makers in the UK, Continental Europe, and the US, sheds new light on one of the central issues facing governments in the advanced industrial countries - how to create and sustain new science-based industries.

"Micropolitics and Canadian Business" explores the internal structure of industry politics in contemporary Canada. This "micropolitics" approach offers a revealing set of conceptual tools and models that illuminate the politics of everyday business at the industry, firm, and policy issue levels. It builds wider contexts in which the concrete particulars of business-government relations can be explored and understood in a systematic fashion.

The approach developed is a comparative one. The book examines three industries--paper, steel, and airlines--carefully chosen to represent a revealing cross-section of a vast economic field covering the primary (resource), secondary (manufacturing), and tertiary (service) sectors of the economy. In addition, one industry (pulp and paper) is primarily export-oriented, another (steel) focuses mainly on domestic sales, and the third (air transport) is strongly grounded in both.

The book applies to each a common set of questions and applies a similar set of methods. Separate chapters on each industry begin with a brief review of current industry concerns, followed by a historical and structural survey of that industry. Each chapter continues with studies of two leading firms, highlighting their internal politics and their strategic orientations. Since firms are the building blocks of industry, they tell us much about the larger structures of political power. Finally, each chapter examines two significant public policy controversies whose scope extends beyond core business boundaries.

"Micropolitics and Canadian Business" specifically analyzes three industries; however, the approach used may be applied to a much wider universe of companies and sectors. Throughout, this book furthers our understanding of the complex contexts of business politics. As such, it will be of interest to both students and practitioners of business and government relations.

A TIMES BEST CURRENT AFFAIRS BOOK OF THE YEAR The award-winning Financial Times columnist exposes the threat that Big Tech poses to our democracies, our economies and ourselves 'Powerful' Sunday Times Google and Facebook receive 90% of the world's news advertising spend. Amazon takes half of all e-commerce in the US. Google and Apple operating systems run on all but 1% of cell phones globally. And 80% of corporate wealth is now held by 10% of companies - the digital titans. How did these once-idealistic and innovative companies come to manipulate elections, violate our privacy and pose a threat to the fabric of our democracy? Through her skilled reporting and unparalleled access, Rana Foroohar reveals the true extent to which the 'FAANG's (Facebook, Apple, Amazon, Netflix and Google) crush or absorb competitors, hijack our personal data and mental space and offshore their exorbitant profits. What's more, she shows how these threats to our democracies, livelihoods and minds are all intertwined. Yet Foroohar also lays out a plan for how we can resist, creating a framework that fosters innovation while protecting us from the dark side of digital technology. 'A masterful critique' Observer 'Insightful and powerfully argued' Daily Mail 'Essential reading ... whip-smart' Niall Ferguson 'Laser vision and trenchant business analysis' Shoshana Zuboff

Scientists in the biotechnology sector have developed a vast array of products and procedures, including drugs, diagnostics, agricultural products and veterinary procedures. This is made possible through various intra- and inter-organizational collaborations between the academic and private sectors, and through the establishment of networks for learning. In Networks for Learning and Knowledge Creation in Biotechnology, Amalya Lumerman Oliver shows how, in many respects, the organizational structure of the industry parallels one of its most important innovations - recombinant DNA (rDNA). She shows how the concept of recombination can be used to explain a number of organizational elements, including new biotechnology firms, the form of university-based spin-offs, scientific entrepreneurship, and trust and contracts in learning collaborations and networks. The result is a stimulating account of how multiple theoretical perspectives can be used to understand the structure of the biotechnology industry.

Why is it that in the '90s, business in California's Silicon Valley flourished, while along Route 128 in Massachusetts it declined? The answer, Annalee Saxenian suggests, has to do with the fact that despite similar histories and technologies, Silicon Valley developed a decentralized but cooperative industrial system while Route 128 came to be dominated by independent, self-sufficient corporations. The result of more than one hundred interviews, this compelling analysis highlights the importance of local sources of competitive advantage in a volatile world economy.

Contemporary Medical Biotechnology Research for Human Health discusses a range of currently available solutions required to defeat the ever-increasing human health challenges. The junction between biotechnology and biomedical/health sciences has led to several improvements in patients' treatment, diagnosis and well-being. The book discusses vital topics ranging from biofilms and UTI, mycobacterial infections, diabetes, aplastic anemia, oral cancer, and possible applications of nanoparticles. In addition, it discusses computer-aided drug design using natural products and new technologies to develop antibiotics. This is a valuable resource for biotechnology and biomedical researchers, bioinformaticians and members of health sciences interested in understanding recent technological developments.

Key Account Management Excellence in Pharma & Medtech is designed to help life sciences practitioners develop and execute innovative and effective key account management (KAM) strategies and capabilities. Pharmaceutical and medtech companies are increasingly pursuing KAM in response to the rapid rise of large, sophisticated and complex healthcare provider and payer systems and groups. Those that invest the time to get KAM right will protect their business and grow with these rising customers. This book is groundbreaking in both its scope and its tailoring of leading KAM practices specifically for life sciences. The central theme is that "key account management is an organization-wide business strategy, not just a role or a sales-specific initiative." KAM is a strategy focused on providing unique offerings and value through an orchestrated, cross-functional, go-to-market model designed specifically to address the needs and engagement preferences of a unique segment of customers. The insights and practices shared in this book are designed to be a valuable reference at every stage of the KAM journey. The book has been designed to facilitate a common language and deep understanding of KAM issues and leading practices organization-wide-particularly for life sciences leaders, account managers and cross-functional team members responsible for building, transforming and supporting their organization's KAM strategies and capabilities.

During the 1970s and 1980s, American manufacturing enterprises saw their technological dominance challenged by increasingly tough competition from abroad. This book investigates business responses to those challenges. On average, F. M. Scherer shows, 308 U.S. companies reacted to rising imports of high-technology products by cutting back research and development expenditures as a percentage of sales. The cutbacks were particularly large in industries protected by voluntary trade restraint agreements and other trade barriers. Using statistical data and eleven in-depth case studies, Scherer finds that company responses to new high-technology competition from abroad were highly diverse. Aggressive reactions predominated in firms producing color film, wet shavers, medical imaging apparatus, fiber optics, and earth-moving equipment. But the efforts of U.S. manufacturers in other lines such as color television, VCRs, and facsimile machines were too meager to repel technologically innovative overseas challengers. Exploring why reactions differed so much from case to case, Scherer finds systematic explanations in such variables as the multinationality of enterprises, domestic market structure, links to academic science bases, and the educational background of top managers. He concludes by offering proposals to improve the competitiveness of American high-technology companies.

Transcultural Artificial Intelligence and Robotics in Health and Social Care provides healthcare professionals with a deeper understanding of the incredible opportunities brought by the emerging field of AI robotics. In addition, it provides robotic researchers with the point-of-view of healthcare professionals to understand what the healthcare sector - as well as the market - really needs from robotics technology. By doing so, the book fills an important gap between both fields in order to leverage new developments and collaborative work in favor of global patients. The book is aimed at the non-technical reader, especially health and social care professionals, and explains in a simple way the technological principles applied in the development of socially assistive humanoid AI robots (SAHR), the values which guide such developments, the ethics related to them, and research approaches in the field, with a focus on achieving a culturally competent SAHR.

Roadmap to Successful Digital Health Ecosystems: A Global Perspective presents evidence-based solutions found on adopting open platforms, standard information models, technology neutral data repositories, and computable clinical data and knowledge (ontologies, terminologies, content models, process models, and guidelines), resulting in improved patient, organizational, and global health outcomes. The book helps engaging countries and stakeholders take action and commit to a digital health strategy, create a global environment and processes that will facilitate and induce collaboration, develop processes for monitoring and evaluating national digital health strategies, and enable learnings to be shared in support of WHO's global strategy for digital health. The book explains different perspectives and local environments for digital health implementation, including data/information and technology governance, secondary data use, need for effective data interpretation, costly adverse events, models of care, HR management, workforce planning, system connectivity, data sharing and linking, small and big data, change management, and future vision. All proposed solutions are based on real-world scientific, social, and political evidence.

Bioinformatics for Everyone provides a brief overview on currently used technologies in the field of bioinformatics-interpreted as the application of information science to biology- including various online and offline bioinformatics tools and softwares. The book presents valuable knowledge in a simplified way to help students and researchers easily apply bioinformatics tools and approaches to their research and lab routines. Several protocols and case studies that can be reproduced by readers to suit their needs are also included.